LeonaBio closed at $4.34 on Nov 5, down 4.93%, 62.8% below its highest close since Jan 12. Volume of 94.7K shares was 1.14× its 20-day average (close to normal).
Split-adjusted performance: -25.6% over one month, -56.0% over six months.
Short interest was 87.3K shares at the Oct 15 settlement, up 355.7% from the prior report (1.8% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LONALeonaBio | $4.34 | −4.93% | −56.0% | — | — | — | $40.9M | |
| EXOZeXoZymes | $4.11 | −4.64% | −58.9% | — | — | — | $38.2M | Compare |
| CRBUCaribou Biosciences | $0.4123 | −7.22% | −78.1% | −43.8% | −1619.9% | — | $44.2M | Compare |
| PTHSPelthos Therapeutics | $9.30 | −8.37% | −62.8% | — | −150.1% | — | $36.6M | Compare |
| INMBINmune Bio | $1.18 | −11.65% | −17.8% | — | — | — | $36.4M | Compare |
| IMAImageneBio | $4.17 | +1.59% | −29.5% | — | — | — | $47.3M | Compare |
| TILInstil Bio | $6.99 | 0.00% | −13.0% | — | — | — | $47.4M | Compare |
| GRMLGreenland Mines | $3.57 | −8.70% | — | — | — | — | $48.9M | Compare |
| ELUTElutia | $0.7509 | −1.15% | −24.8% | −11.6% | −315.0% | 0.6 | $33.3M | Compare |
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
